Genetic Risk Assessment for Periodontal Disease Highlighted during American Dental Association Annual Meeting

Dr. Kenneth S. Kornman of Interleukin Genetics Presents the Value and Use of Genetic Testing in Clinical Dentistry. 

Interleukin’s Genetic Risk Test, PerioPredict^® Awarded “Best New Hygienist Product” by DrBicuspid

WALTHAM, Mass., – October 13, 2014 – Interleukin Genetics, Inc. is pleased to announce that the topic of genetics in relation to periodontal disease was a focus at the 2014 American Dental Association (ADA) Annual Meeting.

During a Saturday morning continuing education course titled, “Introduce Scientific Advances Into Your Clinical Practice”, Interleukin’s Chief Executive Officer Kenneth S. Kornman, DDS, PhD presented on the topic of genetic testing as part of risk stratification for preventive dental care.

Heightened interest in the subject results from the landmark research published in the Journal of Dental Research (June 2013). The University of Michigan Personalized Prevention Study provided important new insights into the prevention of periodontal disease and the significant opportunity to improve oral health through a personalized approach to preventive care that includes genetics. Last month, the study’s authors received the 2014 Clinical Research Award from the American Academy of Periodontology demonstrating the impact of this research on clinical dentistry.

During the ADA annual meeting Dr. Kornman was also presented with a 2014 DrBicuspid Dental Excellence Award, naming PerioPredict^® “Best New Hygienist Product”. The Dental Excellence Awards recognize the very best people, products and services that are helping to improve dental health.  The votes are cast by members of the DrBicuspid.com professional community and DrBicuspid.com readers, and honor the best of what dentistry has to offer.

“We’re truly honored that PerioPredict^® has been recognized with an award by the members of DrBicuspid.com. I am also pleased that the ADA has chosen to dedicate a CE session to the important topic of genetic testing, including the research that supports use of genetics as part of a personalized risk-based approach to preventive care” said Dr. Kornman. “The concept of personalized medicine is not new, but current tools, especially in genomics, now allow us to identify and stratify patients with greater precision. This research is opening new doors for the dental profession in terms of optimizing patient care and early identification and prevention of severe periodontitis in patients who are at increased risk.

About PerioPredict^®

The PerioPredict^® genetic test is quick, easy and painless and is performed by dentists during a routine exam or cleaning. PerioPredic^® measures variations in genes for Interleukin-1 (IL-1), a key mediator of inflammation, and identifies individuals who are at increased risk for moderate to severe periodontal disease. The PerioPredict^® test results provide essential information to the dental professional for assessing prevention and treatment options for their patients. PerioPredict^® is run solely in the Interleukin Genetics CLIA-certified lab in Waltham, MA.  For more information, visit www.PerioPredict.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ flagship products include its proprietary PerioPredict^® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Act (CLIA). For more information, please visit www.ilgenetics.com.

Certain statements contained herein are “forward-looking” statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company’s annual report on Form 10-K for the year ended December 31, 2013 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.